MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach

Bolós, Carme de; Garrido, Marta; Real, Francisco X.

doi:10.1016/0016-5085(95)90379-8

Cited by 253 publications

(205 citation statements)

References 30 publications

Supporting

Mentioning

184

Contrasting

Unclassified

Order By: Relevance

“…With this procedure, the GSDM mRNA was detected predominantly in the pit region among the three regions of pit, isthmus/neck and gland (Figure 1b). The expression of a pit cell marker, mucin 5, subtypes A and C (MUC5AC) (De Bolos et al, 1995;Ho et al, 1995) was significantly higher in the pit region, while a proliferating cell marker, proliferating cell nuclear antigen (PCNA), was detected preferentially in the isthmus/neck region ( Figure 1b). Other specific or preferential expression of three markers (ATP4B, GIF and MUC6) has been confirmed in the gland region by our previous studies (Nishigaki et al, 2005;Fukaya et al, 2006).…”

Section: Resultsmentioning

confidence: 99%

GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-β-dependent apoptotic signalling

Saeki¹,

et al. 2007

View full text Add to dashboard Cite

Defining apoptosis-regulatory cascades of the epithelium is important for understanding carcinogenesis, since cancer cells are considered to arise as a result of the collapse of the cascades. We previously reported that a novel gene GASDERMIN (GSDM) is expressed in the stomach but suppressed in gastric cancer cell lines. Furthermore, in this study, we demonstrated that GSDM is expressed in the mucus-secreting pit cells of the gastric epithelium and frequently silenced in primary gastric cancers. We found that GSDM has a highly apoptotic activity and its expression is regulated by a transcription factor LIM domain only 1 (LMO1) through a sequence to which Runt-related transcription factor 3 (RUNX3) binds, in a GSDM promoter region. We observed coexpression of GSDM with LMO1, RUNX3 and type II transforming growth factor-b receptor (TGF-bRII) in the pit cells, and found that TGF-b upregulates the LMO1-and GSDMexpression in the gastric epithelial cell line and induces apoptosis, which was confirmed by the finding that the apoptosis induction is inhibited by suppression of each LMO1-, RUNX3-and GSDM expression, respectively. The present data suggest that TGF-b, LMO1, possibly RUNX3, and GSDM form a regulatory pathway for directing the pit cells to apoptosis.

show abstract

Section: Resultsmentioning

confidence: 99%

GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-β-dependent apoptotic signalling

Saeki¹,

et al. 2007

View full text Add to dashboard Cite

show abstract

“…HGM is synonymous with MUC5AC and the antibody is known to react with surface foveolar cells in the stomach (Bara et al, 1998;Nollet et al, 2002). MUC6 glycoprotein is expressed in the mucous cells of the neck zone of the oxyntic mucosa and in the antral glands (De Bolos et al, 1995;Reis et al, 1999). MUC2 glycoprotein is an intestinal apomucin, which is also known to be expressed in the supranuclear region of the goblet cells in regions of the stomach showing intestinal metaplasia (Kim and Gum, 1995;Reis et al, 1999).…”

Section: Analysis Of Expressions Of Phenotypic Markersmentioning

confidence: 99%

Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach

et al. 2007

View full text Add to dashboard Cite

Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma. The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two. The clinicopathological findings in 72 cases with C-Ca were examined and compared with those in 170 cases with D-Ca. The phenotypic marker expressions examined were those of human gastric mucin (HGM), MUC6, MUC2 and CD10. Furthermore, the presence of mutations in the APC, K-ras and p53 genes and the microsatellite instability status of the tumour were also determined. C-Ca was associated with a significantly higher incidence of differentiated-type tumours and lymphatic vessel invasion (LVI) as compared with D-Ca (72.2 vs 48.2%, P ¼ 0.0006 and 72.2 vs 55.3%, P ¼ 0.0232, respectively). Oesophageal invasion by the tumour beyond the oesophago-gastric junction (OGJ) was found in 56.9% of cases with C-Ca; LVI in the area of oesophageal invasion was demonstrated in 61% of these cases. Also, LVI was found more frequently in cases of C-Ca with oesophageal invasion than in those without oesophageal invasion (82.9 vs 58.1%, P ¼ 0.0197). The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P ¼ 0.0076). A significantly greater frequency of HGM expression in early-stage C-Ca and significantly lower frequency of MUC2 expression in advanced-stage C-Ca was observed as compared with the corresponding values in cases of D-Ca (78.9 vs 52.2%, P ¼ 0.0402 and 51.5 vs 84.6%, P ¼ 0.0247, respectively). Mutation of the APC gene was found in only one of all cases of C-Ca, and the frequency of mutation of the APC gene was significantly lower in cases of C-Ca than in those of D-Ca (2.4 vs 20.0%, P ¼ 0.0108). The observations in this study suggest that C-Ca is a more aggressive tumour than D-Ca. The differences in biological behavior between C-Ca and D-Ca may result from the different histological findings in the wall of the OGJ and the different genetic pathways involved in the carcinogenesis.

show abstract

“…This antibody is known to react with surface foveolar cells in the stomach (Bara et al, 1998;Nollet et al, 2002). MUC6 glycoprotein is expressed in mucous cells of the neck zone of oxyntic mucosa and in antral glands (De Bolos et al, 1995;Reis et al, 1999;Machado et al, 2000). MUC2 glycoprotein, also known as the 'intestinal-mucin-related protein antigen', is an intestinal apomucin and is known to be also expressed in the supranuclear area of the goblet cells in regions showing intestinal metaplasia in the stomach (Kim and Gum, 1995;Sakamoto et al, 1997;Baldus et al, 1998;Utsunomiya et al, 1998;Reis et al, 1999;Machado et al, 2000).…”

Section: Immunohistochemical Stainingmentioning

confidence: 99%

Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-

et al. 2004

View full text Add to dashboard Cite

Both gastric and intestinal phenotypic markers are known to be expressed in gastric carcinomas, irrespective of their histologic type. In the present study, the relation between gastric and intestinal phenotypic marker expression in gastric carcinomas and the recurrence pattern after surgery was examined. The phenotypic marker expression of the tumour was determined by examining the expression of human gastric mucin (HGM), MUC6, MUC2 and CD10 in 213 advanced gastric carcinomas in 213 patients who had undergone a curative resection (97 died from recurrent gastric carcinoma and 116 were alive without recurrence at the end of the follow-up period). Tumours were classified into gastric (G), gastric and intestinal mixed (GI), intestinal (I) or unclassified (UC) phenotypes according to the immunopositivity of HGM, MUC6, MUC2 and CD10 stainings. The incidence of HGM-positive tumours and MUC2-negative tumours was significantly higher in tumours with peritoneal recurrence than in tumours without recurrence (73.3%, 44 out of 60 cases vs 54.3%, 63 out of 116 (P ¼ 0.022); and 70.0%, 42 out of 60 vs 38.8%, 45 out of 116 (P ¼ 0.0002), respectively). The incidence of G-phenotype tumours was also significantly higher in tumours with peritoneal recurrence than in tumours without recurrence (58.3%, 35 out of 60 cases vs 28.4%, 33 out of 116 (P ¼ 0.0002)). The incidence of MUC2-negative tumours and CD10-positive tumours was significantly higher in tumours with haematogenous recurrence than in tumours without recurrence (62.5%, 20 out of 32 cases vs 38.8%, 45 out of 116 (P ¼ 0.028); and 43.8%, 14 out of 32 vs 23.3%, 27 out of 116 (P ¼ 0.039); respectively). Our present findings show that the gastric and intestinal phenotypic marker expression of the tumour, determined by immunohistochemical staining for HGM, MUC6, MUC2 and CD10, can be used to predict the pattern of gastric carcinoma recurrence after curative resection.

show abstract

MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach

Cited by 253 publications

References 30 publications

GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-β-dependent apoptotic signalling

GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-β-dependent apoptotic signalling

Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach

Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions-

Contact Info

Product

Resources

About